Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
alloCART-19 in Pediatric R/R B-cell ALL
NCT04173988Phase 1Active, not recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Jan 2020
- Primary completion
- Oct 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alloCART-19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Children's Hospital of Fudan University. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jan 2020; status: active, not recruiting.
02
Drugs
alloCART-19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04173988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173988.